Tissue variant effects of heme inhibitors on the mouse cytochrome c oxidase gene expression and catalytic activity of the enzyme complex.
The in vivo effects of heme biosynthesis inhibitors, succinylacetone and CoCl2 on the cytochrome c oxidase (COX) gene expression and enzyme activity in different mouse tissues were investigated. Succinylacetone and CoCl2 showed tissue-specific differences in their ability to modulate heme aa3 content. A single dose of succinylacetone treatment for 8 h reduced the heme aa3 content of kidney mitochondria with no effect on the liver. CoCl2 treatment for 8 h, however, selectively affected the heme aa3 level in the liver. Reduced mitochondrial heme aa3 with both treatments was accompanied by approximately 50% reduced, mitochondrial genome-encoded COX I and II mRNAs and nuclear genome-encoded COX Vb mRNAs, but no change in COX IV mRNA level. Use of isolated mouse liver and brain mitochondrial systems showed a 50-80% reduction in mitochondrial transcription and translation rates in heme-depleted tissues. Blue native gel electrophoresis followed by immunoblot analysis showed that the complex from heme-depleted tissues contained a 30-50% reduction in levels of subunits I, IV, Vb and near normal levels of subunit VIc, indicating altered subunit content. Treatment of submitochondrial particles with protein kinase A and ATP resulted in partial dissociation of COX, suggesting a mechanistic basis for the reduced subunit content of the complex from heme-depleted tissues. Surprisingly, the enzyme from heme-depleted tissues showed twofold to fourfold higher turnover rates for cytochrome c oxidation, suggesting alterations in the kinetic characteristics of the enzyme following heme reduction. This is probably the first evidence that the tissue heme level regulates not only the mammalian COX gene expression, but also the catalytic activity of the enzyme, probably by affecting its stability.
Vijayasarathy
C
C
Laboratories of Biochemistry, Department of Animal Biology, University of Pennsylvania, Philadelphia, USA.
Damle
S
S
Lenka
N
N
Avadhani
N G
NG
D000255:Adenosine Triphosphate / Q000494:pharmacology; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000196:embryology; D002384:Catalysis; D003035:Cobalt / Q000494:pharmacology*; D017868:Cyclic AMP-Dependent Protein Kinases / Q000494:pharmacology; D003576:Electron Transport Complex IV / Q000235:genetics / Q000378:metabolism*; D004790:Enzyme Induction; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006418:Heme / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D006419:Heme Oxygenase (Decyclizing) / Q000096:biosynthesis / Q000235:genetics; D006420:Hemeproteins / Q000096:biosynthesis; D006537:Heptanoates / Q000494:pharmacology*; D007501:Iron / Q000378:metabolism; D007668:Kidney / Q000187:drug effects / Q000201:enzymology; D051379:Mice; D008928:Mitochondria / Q000187:drug effects / Q000201:enzymology*; D008930:Mitochondria, Liver / Q000187:drug effects / Q000201:enzymology; D009097:Multienzyme Complexes / Q000235:genetics / Q000378:metabolism*; D009928:Organ Specificity; D000623:Porphobilinogen Synthase / Q000037:antagonists & inhibitors; D012333:RNA, Messenger / Q000096:biosynthesis
D004791:Enzyme Inhibitors; D006420:Hemeproteins; D006537:Heptanoates; D009097:Multienzyme Complexes; D012333:RNA, Messenger; D003035:Cobalt; D006418:Heme; C020804:succinylacetone; D000255:Adenosine Triphosphate; D007501:Iron; D006419:Heme Oxygenase (Decyclizing); D003576:Electron Transport Complex IV; D017868:Cyclic AMP-Dependent Protein Kinases; D000623:Porphobilinogen Synthase; C018021:cobaltous chloride